Company Description
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide.
The company operates through CAG; Water Quality Products; LPD; and Other segments.
It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community.
The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits.
In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups.
The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers.
IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Country | United States |
IPO Date | Jun 21, 1991 |
Industry | Medical - Diagnostics & Research |
Sector | Healthcare |
Employees | 11,000 |
CEO | Jonathan J. Mazelsky |
Contact Details
Address: One IDEXX Drive Westbrook, Maine United States | |
Website | https://www.idexx.com |
Stock Details
Ticker Symbol | IDXX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000874716 |
CUSIP Number | 45168D104 |
ISIN Number | US45168D1046 |
Employer ID | 01-0393723 |
SIC Code | 2835 |
Key Executives
Name | Position |
---|---|
Jonathan J. Mazelsky | President, Chief Executive Officer & Director |
Brian P. McKeon | Chief Financial Officer, Executive Vice President & Treasurer |
Dr. Martin Smith Ph.D. | Executive Vice President & Chief Technology Officer |
Ken Grady | Senior Vice President & Chief Information Officer |
George J. Fennell | Senior Vice President & Chief Revenue Officer |
Jeffery D. Chadbourne | Senior Vice President of Commercial Finance & Sales Operations |
John Hart | Senior Vice President of Global Operations |
Michael J. Lane | Executive Vice President and GM of Reference Laboratories & Information Technology |
Michael P. Johnson | Executive Vice President & Chief Human Resources Officer |
Sharon E. Underberg J.D. | Executive Vice President, General Counsel, & Corporate Secretary |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 12, 2024 | 8-K | Current Report |
Dec 09, 2024 | 8-K | Current Report |
Nov 29, 2024 | 4 | Filing |
Nov 21, 2024 | 8-K | Current Report |
Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 12, 2024 | 8-K | Current Report |
Nov 06, 2024 | 8-K | Current Report |
Nov 04, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Oct 31, 2024 | 10-Q | Quarterly Report |
Oct 31, 2024 | 8-K/A | [Amend] Current Report |